Abstract
Leukocyte telomere length (LTL) is associated with multiple conditions, including cardiovascular diseases and neoplasms, yet their differential associations across diverse individuals are largely unknown. We estimated LTL from blood-derived whole genome sequences in the All of Us Research Program (n=242,494) with diverse backgrounds across the United States. LTL was associated with lifestyle, socioeconomic status, biomarkers, cardiometabolic diseases, and neoplasms with heterogeneity across genetic ancestries and sexes. Geographical analysis revealed that significantly longer LTL clustered in the West Coast and Central Midwest, while significantly shorter LTL clustered in the Southeast in the United States, accounting for age, sex, and genetic ancestry. Genome-wide association study and meta-analysis with the UK Biobank (n=679,972) found 234 non-overlapping loci, of which 36 were novel. We identified 4 novel loci unique to non-European-like populations and one specific to females. Rare variant analysis uncovered 7 novel genes, providing new functional insights. Our study highlighted previously underappreciated contextual heterogeneities of phenomic and genomic associations with LTL.
Competing Interest Statement
P.N. reports research grants from Allelica, Amgen, Apple, Boston Scientific, Genentech / Roche, and Novartis, personal fees from Allelica, Apple, AstraZeneca, Blackstone Life Sciences, Creative Education Concepts, CRISPR Therapeutics, Eli Lilly & Co, Esperion Therapeutics, Foresite Capital, Foresite Labs, Genentech / Roche, GV, HeartFlow, Magnet Biomedicine, Merck, Novartis, TenSixteen Bio, and Tourmaline Bio, equity in Bolt, Candela, Mercury, MyOme, Parameter Health, Preciseli, and TenSixteen Bio, and spousal employment at Vertex Pharmaceuticals, all unrelated to the present work.
Funding Statement
T.N. is supported by the National Heart Lung Blood Institute (K99HL165024). S.K. is supported by the National Heart Lung Blood Institute (K99HL169733). A.P.P is supported by the National Heart Lung Blood Institute (K08HL168238). P.N. is supported by the National Heart Lung Blood Institute (R01HL168894).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The protocol of the National Institute of Health All of Us Research Program (AoU) was reviewed by the Institutional Review Board (IRB) of the AoU Research Program. The AoU IRB follows the regulations and guidance of the NIH Office for Human Research Protections for all studies, ensuring that the rights and welfare of research participants are overseen and protected uniformly. The UK Biobank Resource was used under application number 7089. Secondary use of the UKB data was approved by the Massachusetts General Hospital institutional review board (2021P002228).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
GWAS summary statistics generated in this study will be publicly available at Cardiovascular Disease Knowledge Portal (https://cvd.hugeamp.org/) upon publication. The estimated LTL will be returned to AoU upon publication. The genotypes and phenotypes of UKB and AoU participants are available by application to the UKB (https://www.ukbiobank.ac.uk/register-apply/) and AoU (https://allofus.nih.gov/), respectively. The previously published GWAS summary statistic for LTL in UKB (https://figshare.com/s/caa99dc0f76d62990195) and meta-analysis (https://figshare.com/s/f6de1a56ad7c448c1f4c) are publicly available. The previously published full GWAS summary statistics for LTL in TOPMed are available upon application on dbGap (phs001974).
